Jevtana

Before taking this medicine

Jevtana (cabazitaxel) must not be used in people with: • A neutrophil count of 1,500/mm³ or lower. Neutrophils are a type of white blood cell. • A history of severe allergic reactions to cabazitaxel or to other medicines formulated with polysorbate 80. • Severe liver impairment, defined as total bilirubin more than three times the upper limit of normal. Extra caution and monitoring are needed in people aged 65 or older, those with haemoglobin below 10 g/dL, and those with mild or moderate liver impairment. Blood counts must be checked frequently because Jevtana can suppress bone marrow function, causing low neutrophil counts and serious or fatal infections. Severe allergic reactions can occur. Medicines are given before treatment to reduce this risk; the infusion must be stopped immediately if a reaction occurs. Other serious risks include severe diarrhoea and dehydration, gastrointestinal bleeding or perforation, bowel inflammation associated with low neutrophil counts, kidney failure, and lung inflammation or acute respiratory distress. Some of these complications have been fatal. Bladder inflammation and blood in the urine can also occur; people who previously received pelvic radiation need monitoring for bladder symptoms. Jevtana can harm an unborn baby and cause pregnancy loss. Men with female partners who could become pregnant should use effective contraception.